Management only reports on first and last patient being injected. Dilution is inevitable without a partnership. But like I asked - what's a few million more shares being issued for a product that is targeting a multibillion dollar market? It's a shame that trials have been delayed this much, but this is not a short term stock flip unless there's a buyout.
News 
Market Data 
Discover 
